NutriPhos (Calcium fructoborate)

Calcium fructoborate (NutriPhos) is a plant-derived boron complex in which boron is chelated to fructose and calcium, enhancing its bioavailability compared to inorganic boron salts. It delivers bioavailable boron that may support bone mineralization and exhibits antioxidant activity by reducing reactive oxygen species (ROS) in cell models.

Origin & History

NutriPhos (Calcium fructoborate) is a branded synthetic calcium salt of a bis(fructose) ester of boric acid, produced as a tetrahydrous crystalline powder. It is chemically synthesized from crystalline fructose, boric acid, and calcium carbonate, forming a fully complexed structure where two fructose molecules bind to a single boron atom, mimicking naturally occurring fructose-borate esters found in fruits, vegetables, and honey.

Historical & Cultural Context

No historical context in traditional medicine systems is documented for calcium fructoborate or NutriPhos. While naturally occurring fructose-borate esters are found in common dietary plants like apples, grapes, onions, and wheat, this reflects modern dietary intake rather than targeted traditional therapeutic applications.

Health Benefits

• May reduce reactive oxygen species (ROS) levels by up to 50% at non-cytotoxic concentrations, suggesting anti-inflammatory potential (in vitro evidence only)
• Provides bioavailable boron (6 mg per 220 mg serving) which may support bone health (theoretical benefit, no human trials provided)
• Acts as a controlled-release boron source without reverting to free boric acid in tissues (animal data only)
• May offer enhanced absorption via sugar-active transporters compared to inorganic borate (mechanistic evidence only)
• Demonstrates safety with no mutagenicity or genotoxicity in preclinical studies (90-day rat NOAEL: 1,200 mg/kg/day)

How It Works

Calcium fructoborate releases ionic boron after digestion, which is thought to modulate the activity of enzymes involved in steroid hormone metabolism, potentially increasing serum levels of 17β-estradiol and testosterone, both of which play roles in bone remodeling via osteoblast stimulation. Boron also appears to inhibit nuclear factor-kappa B (NF-κB) signaling, a key transcription factor driving pro-inflammatory cytokine production, which may partly explain the observed reduction in reactive oxygen species (ROS). Additionally, the fructoborate complex may interact with cellular antioxidant pathways, including superoxide dismutase (SOD) upregulation, though these mechanisms remain primarily characterized in in vitro models.

Scientific Research

The research dossier lacks details on human clinical trials, RCTs, or meta-analyses specifically for NutriPhos (calcium fructoborate), with no PubMed PMIDs provided. Short-term human studies demonstrate tolerability at up to 220 mg/day in adults, but study design, sample size, and efficacy endpoints are not detailed. Evidence is primarily limited to in vitro anti-inflammatory data via ROS reduction and animal safety studies.

Clinical Summary

The primary evidence for NutriPhos (calcium fructoborate) at this stage is limited to in vitro studies demonstrating up to 50% reduction in ROS at non-cytotoxic concentrations, with no peer-reviewed human clinical trials specifically on this branded form provided. General boron research in humans suggests that dietary boron intakes of 3–10 mg/day can positively influence markers of bone metabolism, including serum calcium and magnesium retention, but these findings cannot be directly extrapolated to NutriPhos without dedicated trials. The theoretical bone health benefit derives from boron's known role in modulating sex hormone levels and mineral metabolism rather than direct fracture or bone density endpoint data. Overall, the current evidence is preliminary and largely mechanistic; robust randomized controlled trials in humans are needed to substantiate efficacy claims.

Nutritional Profile

{"macronutrients": {"protein": "Not applicable", "fiber": "Not applicable", "fat": "Not applicable", "carbohydrates": "Not applicable"}, "micronutrients": {"calcium": "Not specified", "boron": "6 mg per 220 mg serving"}, "bioactive_compounds": {"calcium fructoborate": "220 mg per serving"}, "bioavailability_notes": "Provides bioavailable boron, acts as a controlled-release boron source without reverting to free boric acid in tissues (based on animal data)."}

Preparation & Dosage

Clinically studied dosage: 220 mg/day of calcium fructoborate powder for adults aged 19+, providing 6 mg boron, 10 mg calcium, and 191 mg fructose per serving. This equates to approximately 3 mg/kg body weight/day for a 70 kg individual. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin D3, Calcium citrate, Magnesium glycinate, Vitamin K2, Collagen peptides

Safety & Interactions

Calcium fructoborate is generally considered safe at supplemental doses providing up to 6 mg of boron per serving, consistent with the tolerable upper intake level (UL) for boron set at 20 mg/day for adults by the Institute of Medicine. High boron intake above the UL may cause nausea, vomiting, diarrhea, and in extreme cases nephrotoxicity, though such effects are not associated with typical supplement doses. Because boron may influence estrogen and testosterone metabolism, individuals with hormone-sensitive conditions (e.g., estrogen receptor-positive breast cancer, endometriosis) or those on hormone replacement therapy or anticoagulants should consult a physician before use. Safety data in pregnant or breastfeeding women is insufficient, and use during pregnancy is not recommended without medical supervision.